Stages infirmiers et hospitaliers de la PASS à la FASM3 - Faculté de Médecine et de Maïeutique Lyon Sud - Charles Mérieux
![Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/4eb8a236-ded3-4c80-b01b-23436bc85d78/gr1.jpg)
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology
Stages infirmiers et hospitaliers de la PASS à la FASM3 - Faculté de Médecine et de Maïeutique Lyon Sud - Charles Mérieux
![Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/90d1b80a-4211-46d8-9c29-47c4fb8257e7/gr1.jpg)